Company intelligence / Profile preview

Epiphany Biosciences

San Francisco, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~1
Development stage: Phase 2

Overview

Epiphany Biosciences was a San Francisco-based biotechnology company focused on developing antiviral therapeutics and diagnostics for viral diseases with unmet medical needs. Its lead candidate, Valomaciclovir (EPB‑348), advanced to Phase 2b clinical trials targeting shingles. The company also developed screening diagnostics for HHV‑8/KSHV. Founded by prominent virologists including several Lasker Award winners, the company raised $36 million in Series A financing but appears to have ceased operations in recent years.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (notably antiviral therapeutics such as Valomaciclovir/EPB‑348)
Industry: Biotech

Drug pipeline

1 asset

valomaciclovir

Phase 2

Indications: Shingles

Beyond the preview

Go deeper on Epiphany Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epiphany Biosciences.

Explore the full profile